230 related articles for article (PubMed ID: 16687179)
1. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Davis DA; Brown CA; Singer KE; Wang V; Kaufman J; Stahl SJ; Wingfield P; Maeda K; Harada S; Yoshimura K; Kosalaraksa P; Mitsuya H; Yarchoan R
Antiviral Res; 2006 Nov; 72(2):89-99. PubMed ID: 16687179
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
3. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
[TBL] [Abstract][Full Text] [Related]
4. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.
Baraz L; Friedler A; Blumenzweig I; Nussinuv O; Chen N; Steinitz M; Gilon C; Kotler M
FEBS Lett; 1998 Dec; 441(3):419-26. PubMed ID: 9891983
[TBL] [Abstract][Full Text] [Related]
6. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
Lindhofer H; von der Helm K; Nitschko H
Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid Cu1+.
Davis DA; Branca AA; Pallenberg AJ; Marschner TM; Patt LM; Chatlynne LG; Humphrey RW; Yarchoan R; Levine RL
Arch Biochem Biophys; 1995 Sep; 322(1):127-34. PubMed ID: 7574666
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
[TBL] [Abstract][Full Text] [Related]
9. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.
Misumi S; Kudo A; Azuma R; Tomonaga M; Furuishi K; Shoji S
Biochem Biophys Res Commun; 1997 Dec; 241(2):275-80. PubMed ID: 9425262
[TBL] [Abstract][Full Text] [Related]
10. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
[TBL] [Abstract][Full Text] [Related]
11. C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.
Yu FH; Huang KJ; Wang CT
J Virol; 2017 May; 91(10):. PubMed ID: 28250114
[TBL] [Abstract][Full Text] [Related]
12. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
Stoddart CA; Liegler TJ; Mammano F; Linquist-Stepps VD; Hayden MS; Deeks SG; Grant RM; Clavel F; McCune JM
Nat Med; 2001 Jun; 7(6):712-8. PubMed ID: 11385509
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.
Whitehurst N; Chappey C; Petropoulos C; Parkin N; Gamarnik A
AIDS Res Hum Retroviruses; 2003 Sep; 19(9):779-84. PubMed ID: 14585208
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
Karacostas V; Wolffe EJ; Nagashima K; Gonda MA; Moss B
Virology; 1993 Apr; 193(2):661-71. PubMed ID: 7681610
[TBL] [Abstract][Full Text] [Related]
18. Role of capsid sequence and immature nucleocapsid proteins p9 and p15 in Human Immunodeficiency Virus type 1 genomic RNA dimerization.
Kafaie J; Dolatshahi M; Ajamian L; Song R; Mouland AJ; Rouiller I; Laughrea M
Virology; 2009 Mar; 385(1):233-44. PubMed ID: 19070880
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
Park J; Morrow CD
Virology; 1993 Jun; 194(2):843-50. PubMed ID: 8503189
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
